Indo-European Consortium for Next Generation Influenza Vaccine Innovation
Indo-European Consortium for Next Generation Influenza Vaccine Innovation (INCENTIVE) is a large research consortium funded by the EU H2020 program. The strategic goals of the INCENTIVE project are to advance knowledge of the underlying mechanisms of poor responsiveness to influenza vaccines (IVs) and to develop two next-generation universal IVs. This is a partnership between Indian, European and US groups that address the global health and economic challenge posed by influenza infections.
The objectives include: performing comprehensive profiling of responders and non-responders to licensed IVs in infants, children, adults and elderly in phase IV trials in Europe and India to identify the mechanisms of vaccine responsiveness; advancing the development of two next-generation vaccines by providing a proof-of-concept for vaccine efficacy in non-human primates for an antigen presenting cell-targeted nucleic acid vaccine and developing a computationally-optimized vaccine up to phase II clinical trials and vaccine efficacy in a controlled human challenge; identifying predictive biomarkers of responsiveness to vaccination for new diagnostics; implementing technology transfer; and performing a health systems and investment analysis.
INCENTIVE is coordinated by Helmholtz-Zentrum für Infektionsforschung GmbH, Germany. EVF provides the scientific project management support to the program.
For more information, visit website